Clinical Trial Search

Primary: Sustained Virologic Response (SVR) Rate — 40.2; 66.8; 68.5; 23.1 Percentage of participants — p=<0.0001

Primary: Overall Survival — 11.1; 9.0 months — p=0.1403

Primary: The Primary Measure of Efficacy Was the Percent Change in the "Average Pain for the Past 24 Hours" Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to…

Primary: Absolute Change in Percent Predicted Forced Vital Capacity(FVC) — -9; -10 Change in Percent Predicted FVC

Primary: Absolute Change in Percent Predicted Forced Vital Capacity (FVC) — -8.0; -10.0; -12.4 Change in Percent Predicted FVC

Primary: The Primary Outcome Measure Was the Number of Participants With New Heparin Platelet Factor 4 (HIT Positive) Antibodies in Each Group Within 30 Days Following Surgery…

Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks — -3.0; -4.8; -4.7; -5.5 Units on a scale — p=0.003

Primary: Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug — 80; 89.5; 69.6 percent of headaches

Primary: Number Adherent With the Intervention — 29 participants

Primary: Overall Survival — 120; 92; 81 Participants

Primary: Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set) — 66.79…

Primary: Subject-reported Pain Associated Immediately After Each Injection — 11.89; 8.64 Scores on a scale

Primary: Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age — 72; 77; 60; 56 Percentages of subjects

Primary: Number of Patients With Undetectable Human Immunodeficiency Virus (HIV) Viral Load at Week 24. — 49 participants

Primary: Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8 — -29.0; -22.9 mmHg — p=0.0001